Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Barbara Seliger

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

B. Seliger

Author affiliations

  • Institute Of Medical Immunology, Martin Luther University of Halle, 06112 - Halle/DE
More

Resources

Abstract 5018

Background

The Geparnuevo trial is a randomized, double-blind, multi-center phase II trial of neoadjuvant therapy in patients with early-stage triple negative breast cancer (TNBC) investigating the role of durvalumab, an anti-PD-L1 inhibitor in addition to standard chemotherapy with nab-paclitaxel followed by epirubicin plus cyclophosphamide.

Methods

In order to determine possible predictive and / or prognostic biomarkers, blood samples were taken before and during the different treatment phases and evaluated by multicolor flow cytometry.

Results

Evaluation of the absolute cell count in the whole blood highlighted a mixed behavior of the total leukocytes, whereas there was a statistically significant reduction in the lymphocytes, particularly during the last phase of the treatment. Further dissection into the different immune populations highlighted an almost complete loss of B cells that in some patients was also accompanied by a reduction of NK cells, mostly regarding the CD16+ subset. However, the loss of CD4+ and CD8+ T cells has been less pronounced resulting in an overall enhancement of their percentages within the total lymphocytes. The different populations have also been evaluated for the expression of activation and exhaustion markers, whose behavior will be more deeply evaluated when the clinical outcome and the treatment received by the various patients will be made available.

Conclusions

We expect that with such analysis possible biomarkers for the treatment of TNBC patients will be identified thus leading to better patient selection for chemo/immune combination therapy.

Clinical trial identification

Legal entity responsible for the study

GBG.

Funding

AstraZeneca and Celgene.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings